Precision Dermatology, Inc. Patent applications |
Patent application number | Title | Published |
20140243423 | Stable, Non-Irritating Topical Formulations of Hydroquinone - Described herein are methods and compositions for increasing the efficacy and decreasing the irritancy of topical formulations of hydroquinone. | 08-28-2014 |
20140243300 | Controlling the Bioavailability of Active Ingredients in Topical Formulations - Described are methods and compositions for tuning the bioavailability of an active agent, such as a corticosteroid, in a topical formulation. | 08-28-2014 |
20140243299 | Topical Formulations of Corticosteroids with Enhanced Bioavailability - Described herein are methods and compositions for increasing the bioavailability of a corticosteroid, such as hydrocortisone 17-butyrate, in a topical formulation. | 08-28-2014 |
20140170251 | Topical Formulations for Increasing the Dermal Concentration of Hyaluronic Acid - Described herein are methods and compositions for increasing dermal concentrations of glycosaminoglycans (GAG), including hyaluronic acid. Exemplary methods involve a one-step protocol and a three-step protocol. Either method can be used over a 90-day treatment period. | 06-19-2014 |
20140140937 | Foamable Benzoyl Peroxide Compositions for Topical Administration - Described herein are benzoyl peroxide compositions useful in the treatment of acne and other skin conditions, which exhibit enhanced stability, even under accelerated conditions. The compositions also exhibit reduced color formation, reduced irritation, and enhanced moisturizing properties. They can be formulated into a topical aerosol foam with inert, non-flammable propellants, such as hydrofluoroalkanes, and may be used in cosmetics or pharmaceuticals. Additionally, methods of formulating these compositions are described. | 05-22-2014 |
20140134112 | Topical Pharmaceutical Foam Composition - A stable topical alcohol-free aerosol foam containing one or more keratolytic agents is provided. The foam-forming formulation is an oil-in-water emulsion which contains one or more hydrofluoroalkane (HFA) propellants and one or more keratolytic agents. The keratolytic agent may be present in either phase of the emulsion or dispersed in the emulsion. The oil phase may consist at least in part of the HFA propellant. The foam is stable on the skin for at least 5 minutes at body temperature and disappears into the skin upon rubbing or after prolonged standing. The formulations may not contain additional co-solvents or non-HFA co-propellants. The formulations demonstrate reduced intensity of the odor and/or color associated with the keratolytic agent(s) as compared to conventional formulations containing keratolytic agents. | 05-15-2014 |
20140017182 | Topical Formulations Comprising DNA Repair Enzymes, and Methods of Use Thereof - Disclosed are methods of decreasing or preventing UV-induced skin damage, comprising the step of applying to an area of skin an effective amount of a topical formulation comprising a photolyase and an endonuclease. In certain embodiments, the formulation is applied before and after UV exposure. | 01-16-2014 |
20130253015 | Cyclodextrin-Based Microemulsions, and Dermatological Uses Thereof - Described herein are cyclodextrin-stabilized microemulsion systems useful for increasing the solubility, stability, bioavailability, or safety of an active agent for delivery to the skin. The microemulsions may reduce the occurrence of skin irritation or odor upon application. In certain embodiments, the active agent is substantially insoluble in water. | 09-26-2013 |
20130253014 | Cyclodextrin-Based Microemulsions, and Dermatological Uses Thereof - Described herein are cyclodextrin-stabilized microemulsion systems useful for increasing the solubility, stability, bioavailability, or safety of an active agent for delivery to the skin. The microemulsions may reduce the occurrence of skin irritation or odor upon application. | 09-26-2013 |
20130251644 | Cyclodextrin-Based Microemulsions, and Dermatological Uses Thereof - Described herein are cyclodextrin-stabilized microemulsion systems useful for increasing the solubility, stability, bioavailability, or safety of an active agent for delivery to the skin. The microemulsions may reduce the occurrence of skin irritation or odor upon application. In certain embodiments, the active agent is substantially insoluble in water. The microemulsions may be formulated as semi-solids, for example creams, or as aerosol or non-aerosol foams. Also described are methods of treating skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive microemulsion. | 09-26-2013 |
20130115173 | Stable Dermatological Aerosol Foams Utilizing Reactive Propellants - Described herein are chemically-stabile formulations comprising a reactive propellant. The formulations are delivered as an aerosol foam, and are suitable for topical application. The aerosol propellant may be a hydrofluoroolefin propellant. The emulsions or compositions may comprise reactive active agents, such as peroxides, retinoids, or quinones. Also described are methods of treating skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition. | 05-09-2013 |
20130085957 | METHOD AND SYSTEM FOR AUTOMATIC PRODUCT REPLENISHMENT - A computer-implemented method and system are provided for automatic product replenishment. The method includes the steps of: (a) receiving an order for products to be sent to a customer on a given replenishment schedule; (b) determining a product replenishment plan for evolving the products to be sent to the customer to improve product performance; and (c) automatically sending products to the customer in accordance with the product replenishment plan over the replenishment schedule. | 04-04-2013 |
20120189557 | Topical Delivery with a Carrier Fluid - Aerosol spray formulations capable of delivering high concentrations of active agent-containing materials and/or excipient are described herein. The formulation contains a carrier fluid, a propellant and a therapeutic, prophylactic, cosmeticeutical and/or inert solid suspended, dissolved, or dispersed in the formulation. The active ingredient may be an antibiotic, an antihistamine, an anesthetic, an anti-inflammatory, and/or an astringent. In one embodiment, the active agent is an antifungal agent. In another embodiment, the active agent is a cosmeticeutical. The active agent can optionally be dispersed on, or associated with, a carrier powder. The carrier fluid is a highly volatile silicone liquid, which evaporates in less than | 07-26-2012 |
20120148516 | Tandem Hypochlorite-Barrier Repair Therapy for the Treatment of Eczema - Described herein are compositions, kits, and methods for the treatment of atopic dermatitis and related dermatological disorders. The invention encompasses a two-step method of treating a condition, wherein the first step involves applying an inventive bleach composition to the skin, and the second step involves applying an inventive barrier repair composition to the skin. | 06-14-2012 |
20120128598 | Topical Pharmaceutical Foam Composition - A stable topical alcohol-free aerosol foam containing one or more keratolytic agents is provided. The foam-forming formulation is an oil-in-water emulsion which contains one or more hydrofluoroalkane (HFA) propellants and one or more keratolytic agents. The keratolytic agent may be present in either phase of the emulsion or dispersed in the emulsion. The oil phase may consist at least in part of the HFA propellant. The foam is stable on the skin for at least 5 minutes at body temperature and disappears into the skin upon rubbing or after prolonged standing. The formulations may not contain additional co-solvents or non-HFA co-propellants. The formulations demonstrate reduced intensity of the odor and/or color associated with the keratolytic agent(s) as compared to conventional formulations containing keratolytic agents. | 05-24-2012 |
20110305643 | High Oil-Content Emollient Aerosol Foam Compositions - Described herein are high oil-content emulsions and compositions for the treatment of inflammatory skin disorders. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise active agents, such as corticosteroids. Also described are methods of treating inflammatory skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition. | 12-15-2011 |
20110236321 | Aerosol Foams Comprising Clindamycin Phosphate - Described herein are emulsions and compositions for the treatment of acne vulgaris. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise clindamycin phosphate and a buffer salt, and may exhibit decreased rates of clindamycin phosphate hydrolysis. Also described are methods of treating acne vulgaris, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition. | 09-29-2011 |